The adenocarcinoma showed epidermal growth factor receptor (EGFR) mutation, no anaplastic lymphoma kinase (ALK) expression, and less than 1% expression of programmed death ligand 1 (PD-L1) by immunohistochemistry. This evidence concerns the gene ALK and adenocarcinoma.